DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03034941

CompletedPhase 4

Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients

Short Term Weight Loss With Liraglutide and Metformin Before IVF in Infertile Obese PCOS Patients

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

35

actual

Study population

Obesity / overweight, PCOS, Reproductive / infertility

Key I/E criterion

•Female

Primary endpoint

•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03034941
Org study IDObesity,PCOS and IVF

Timeline

Milestones

Study first posted2017-01-27estimated
Last update posted2017-01-27estimated
Study start2014-04 (month precision)
Primary completion2016-12actual (month precision)
Study completion2016-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightPCOSReproductive / infertility

Eligibility

Who can enroll

Minimum age18 Years
Maximum age38 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•polycystic ovary syndrome (rotterdam criteria)
•BMI of 30 kg/m² or higher
•Infertility for IVF with normal male sperm

Exclusion criteria

•type 1 or type 2 diabetes mellitus
•history of carcinoma
•Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
•personal or family history of multiple endocrine neoplasia 2
•significant cardiovascular, kidney or hepatic disease
•the use of medications known or suspected to affect reproductive or metabolic functions
•the use of statins, within 90 days prior to study entry

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Weight & body composition
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

The main outcome was change in BMI

Time frame:Patient's BMI was measured at the beginning and every four weeks during 12 weeks of clinical trial.

BMI, change

change from baseline, improvement

Other clinical outcomes

2 endpoints
Secondary/protocol endpoint/low confidence

Impact of the short term weight loss 5% or more before IVF on oocyte maturity in infertile obese PCOS population.

Time frame:patients were introduced to IVF one month after completed weight loss therapy

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Impact of the short term weight loss 5% or more before IVF on oocyte number of blastocysts in infertile obese PCOS population.

Time frame:patients were introduced to IVF one month after completed weight loss therapy

change from baseline, improvement

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.